Enanta officer reports performance-based stock awards

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock.

Rhea-AI Filing Summary

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported equity compensation transactions in Enanta common stock. On February 12, 2026, she acquired 1,575 shares through performance share units that vested based on 2024-2025 research and development milestones, as determined by the Compensation Committee. She also acquired 4,987 shares from a relative total stockholder return unit award tied to Enanta’s stock performance versus the Nasdaq Biotech Index over matching 60-day periods two years apart. To cover withholding taxes from these awards, 3,257 shares were automatically forfeited at a price of $14.25 per share. Following these transactions, she directly held 33,925 shares of Enanta common stock.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Kieffer Tara Lynn

Role Chief Product Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,575	$0.00	$0.00
Grant/Award	Common Stock	4,987	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	3,257	$14.25	$46K

Holdings After Transaction: Common Stock — 33,925 shares (Direct)

Footnotes (3)

1. F1. Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.
2. F2. Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.
3. F3. Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ENTA’s Chief Product Strategy Officer report?

Tara Lynn Kieffer reported equity compensation transactions in Enanta common stock. She received vested shares from performance-based awards and had a portion of shares automatically forfeited to cover withholding tax obligations related to those awards.

How many Enanta (ENTA) shares did Tara Lynn Kieffer acquire through awards?

She acquired 1,575 shares from performance share units and 4,987 shares from a relative total stockholder return award. Both awards vested based on multi-year performance criteria and were settled in Enanta common stock on February 12, 2026.

Why were 3,257 Enanta (ENTA) shares forfeited in this Form 4 filing?

The 3,257 Enanta shares were automatically forfeited to cover withholding taxes. These taxes arose when performance share units and a relative total stockholder return unit award settled in stock for Tara Lynn Kieffer on February 12, 2026.

What performance metrics triggered the PSU vesting for Enanta (ENTA)?

The performance share units vested based on research and development milestones over the 2024-2025 calendar period. Enanta’s Compensation Committee evaluated performance against these two-year milestones before the units settled into common stock on February 12, 2026.

How was the relative total stockholder return award measured for ENTA?

The rTSRU award was tied to Enanta’s total stockholder return versus component companies in the Nasdaq Biotech Index. Performance was measured over the same 60-day calendar periods two years apart, with results determined by the Compensation Committee before share settlement.

How many Enanta (ENTA) shares does Tara Lynn Kieffer own after these transactions?

After the reported equity compensation and tax-withholding transactions, Tara Lynn Kieffer directly owned 33,925 shares of Enanta common stock. This figure reflects the net impact of vested awards received and shares forfeited to satisfy withholding tax obligations.

What is the role of Enanta’s Compensation Committee in these ENTA awards?

Enanta’s Compensation Committee determined whether performance conditions were met for both the performance share units and the relative total stockholder return award. Their assessment governed vesting outcomes and the resulting share issuances on February 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kieffer Tara Lynn

(Last) (First) (Middle)

C/O ENANTA PHARMACEUTICALS, INC.

4 KINGSBURY AVENUE

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENANTA PHARMACEUTICALS INC [ ENTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Product Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		1,575(1)	A	$0	32,195	D
Common Stock	02/12/2026		A		4,987(2)	A	$0	37,182	D
Common Stock	02/12/2026		F		3,257(3)	D	$14.25	33,925	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Enanta common stock issued under performance share units ("PSUs") that vested as a result of performance against two-year research and development milestones in the calendar 2024-2025 period as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 12, 2026.

2. Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over the same 60-day calendar periods two years apart. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 12, 2026.

3. Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards.

	/s/ Matthew Kowalsky as attorney-in-fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.